Cytokinetics
CYTK
347 hedge funds and large institutions have $6.18B invested in Cytokinetics in 2024 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 120 increasing their positions, 134 reducing their positions, and 47 closing their positions.
77% more call options, than puts
Call options by funds: $182M | Put options by funds: $103M
4% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 47
0% more funds holding
Funds holding: 347 → 347 (0)
0% more funds holding in top 10
Funds holding in top 10: 15 → 15 (0)
4.51% less ownership
Funds ownership: 115.81% → 111.3% (-4.5%)
10% less repeat investments, than reductions
Existing positions increased: 120 | Existing positions reduced: 134
14% less capital invested
Capital invested by funds: $7.2B → $6.18B (-$1.02B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$97.1M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$56.9M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$55.2M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$46.1M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$44.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$239M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$92.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$67.5M |
| 4 |
AC
Armistice Capital
New York
|
-$30.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$28M |
CYTK Hedge Fund Activity: Q4 2024 in Review
347 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2024, worth a combined $6.18B — down 14% from $7.2B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new CYTK positions and 47 closed out — a net gain of 2 holders — while 120 added to existing stakes and 134 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $97.1M. The largest seller was Bank of America, cutting an estimated $239M.
- 347 institutional investors held Cytokinetics (CYTK) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $6.18B of Cytokinetics stock for Q4 2024, down 14% quarter-over-quarter.
- 49 funds opened new Cytokinetics positions in Q4 2024 and 47 closed out, a net change of +2 holders.
- The largest Cytokinetics buyer in Q4 2024 was Deep Track Capital, an estimated $97.1M added.
- The largest Cytokinetics seller in Q4 2024 was Bank of America, an estimated $239M sold.
Based on aggregated 13F filings for Q4 2024.